These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 36253005)

  • 21. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surgery for advanced epithelial ovarian cancer.
    Hacker NF; Rao A
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():71-87. PubMed ID: 27884789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy before definite operative approach for women with advanced-stage epithelial ovarian cancer.
    Wang PH
    Taiwan J Obstet Gynecol; 2018 Oct; 57(5):623-624. PubMed ID: 30342639
    [No Abstract]   [Full Text] [Related]  

  • 24. Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation.
    Nasser S; Lazaridis A; Evangelou M; Jones B; Nixon K; Kyrgiou M; Gabra H; Rockall A; Fotopoulou C
    Gynecol Oncol; 2016 Nov; 143(2):264-269. PubMed ID: 27586894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of radiotherapy in ovarian cancer.
    Durno K; Powell ME
    Int J Gynecol Cancer; 2022 Mar; 32(3):366-371. PubMed ID: 35256425
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sub-optimal primary surgery leads to unfavorable immunological changes in ovarian cancer patients.
    Nowak M; Głowacka E; Lewkowicz P; Banasik M; Szyłło K; Zimna K; Bednarska K; Klink M
    Immunobiology; 2018 Jan; 223(1):1-7. PubMed ID: 29017822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Ovarian Cancer: Weighing the Risks and Benefits of Surgery.
    Kumar A; Cliby WA
    Clin Obstet Gynecol; 2020 Mar; 63(1):74-79. PubMed ID: 31725415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Technical essentials and safety analysis of "rolling carpet" cytoreduction surgery in stage Ⅲc epithelial ovarian cancer].
    Liu H; Shi Y; Zhang GN; Yu J; Xu SQ; Wang DF; Fan Y; Song SQ; Zhou FZ
    Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):521-528. PubMed ID: 32854476
    [No Abstract]   [Full Text] [Related]  

  • 29. Complete tumor resection and demonstration of detailed anatomy of the porta hepatis in a patient with recurrent epithelial ovarian cancer.
    Taskiran C; Vatansever D; Misirlioglu S; Giray B; Kumcular T; Arvas M; Erkan M
    Int J Gynecol Cancer; 2021 Jan; 31(1):148-149. PubMed ID: 33303569
    [No Abstract]   [Full Text] [Related]  

  • 30. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of computed tomography-based sarcopenia and the prognostic value of skeletal muscle index and muscle attenuation amongst women with epithelial ovarian malignancy: A systematic review and meta-analysis.
    Tranoulis A; Kwong FLA; Lakhiani A; Georgiou D; Yap J; Balega J
    Eur J Surg Oncol; 2022 Jul; 48(7):1441-1454. PubMed ID: 35260290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Progress in preoperative evaluation methods regarding cytoreduction in patients with advanced ovarian cancer].
    Liu J; Zhang K
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Jul; 42(7):854-859. PubMed ID: 28845013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
    Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
    Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to: Correspondence on 'The Cukurova score in the prediction of primary cytoreduction in ovarian cancer' by Verit et al.
    Khatib G
    Int J Gynecol Cancer; 2024 May; 34(5):798. PubMed ID: 38453175
    [No Abstract]   [Full Text] [Related]  

  • 35. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
    J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of the PlasmaJet® Device in advanced stage ovarian carcinoma: a systematic review.
    Nieuwenhuyzen-de Boer GM; van der Kooy J; van Beekhuizen HJ
    J Ovarian Res; 2019 Jul; 12(1):71. PubMed ID: 31362769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic Resection as Part of Cytoreductive Surgery in Advanced-stage and Recurrent Epithelial Ovarian Cancer--A Single-center Experience.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Jul; 35(7):4125-9. PubMed ID: 26124365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posterior pelvic exenteration, a crucial component in the surgeon's toolbox for optimizing surgical cytoreduction for advanced ovarian cancer.
    Moukarzel LA; Chi DS
    J Gynecol Oncol; 2022 May; 33(3):e41. PubMed ID: 35320890
    [No Abstract]   [Full Text] [Related]  

  • 40. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.